Byrnes, D. (2022). FTA Standards Development Program: Over-the-Counter and Prescription Drug Use in the Public Transit Industry, Final Report (Report No. FTA Report No. 0217). United States. Department of Transportation. Federal Transit Administration. https://doi.org/10.21949/1520703
Byrnes, Diana. FTA Standards Development Program: Over-the-Counter and Prescription Drug Use in the Public Transit Industry, Final Report. Report no. FTA Report No. 0217. United States. Department of Transportation. Federal Transit Administration, 2022. https://doi.org/10.21949/1520703.
Byrnes, Diana FTA Standards Development Program: Over-the-Counter and Prescription Drug Use in the Public Transit Industry, Final Report. United States. Department of Transportation. Federal Transit Administration, 2022, Report no. FTA Report No. 0217, ROSA P. https://doi.org/10.21949/1520703.
This report includes background research and analysis on the need for new standards, recommended practices, guidance documents, or procedural considerations in the areas of prescription (Rx) and over-the-counter (OTC) medication risk management. Gaps that exist in current standards, recommended practices, or guidance documents available to the industry to address Rx/OTC use are identified, and findings are included that address the development or issuance of voluntary standards, protocols, guidelines, or recommended practices related to Rx/OTC risk management and associated topics.
Byrnes, D. (2022). FTA Standards Development Program: Over-the-Counter and Prescription Drug Use in the Public Transit Industry, Final Report (Report No. FTA Report No. 0217). United States. Department of Transportation. Federal Transit Administration. https://doi.org/10.21949/1520703
Byrnes, Diana. FTA Standards Development Program: Over-the-Counter and Prescription Drug Use in the Public Transit Industry, Final Report. Report no. FTA Report No. 0217. United States. Department of Transportation. Federal Transit Administration, 2022. https://doi.org/10.21949/1520703.
Byrnes, Diana FTA Standards Development Program: Over-the-Counter and Prescription Drug Use in the Public Transit Industry, Final Report. United States. Department of Transportation. Federal Transit Administration, 2022, Report no. FTA Report No. 0217, ROSA P. https://doi.org/10.21949/1520703.
ROSA P serves as an archival repository of USDOT-published products including scientific
findings, journal articles, guidelines, recommendations, or other information authored or co-authored by
USDOT or funded partners. As a repository, ROSA P retains documents in their original published format to
ensure public access to scientific information.
Links with this icon indicate that you are leaving a Bureau of Transportation
Statistics (BTS)/National Transportation Library (NTL)
Web-based service.
Thank you for visiting.
You are about to access a non-government link outside of
the U.S. Department of Transportation's National
Transportation Library.
Please note: While links to Web sites outside of DOT are
offered for your convenience, when you exit DOT Web sites,
Federal privacy policy and Section 508 of the Rehabilitation
Act (accessibility requirements) no longer apply. In
addition, DOT does not attest to the accuracy, relevance,
timeliness or completeness of information provided by linked
sites. Linking to a Web site does not constitute an
endorsement by DOT of the sponsors of the site or the
products presented on the site. For more information, please
view DOT's Web site linking policy.
To get back to the page you were previously viewing, click
your Cancel button.